OncoMatch/Clinical Trials/NCT06603870
Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis
Official title: Secondary Prevention of Venous Thromboembolism in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis (STREAM-Line Study)
Is NCT06603870 recruiting? Yes, currently enrolling (Oct 2026). This Phase 4 trial studies Anticoagulation Therapy for venous thromboembolism.
Treatment: Anticoagulation Therapy — This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Prior therapy
Must have received: therapeutic anticoagulation
treated with any standard therapeutic anticoagulation (including LMWH dose reduction to 75% after the first month) for at least 3 months
Lab requirements
Blood counts
platelet count < 50 x 10^9/L excluded
Kidney function
creatinine clearance < 30 ml/min excluded
Platelet count < 50 x 10^9/L or creatinine clearance < 30 ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06603870 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received therapeutic anticoagulation.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify